Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gel for infected wounds enters first human test

NCT ID NCT07379684

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 18, 2026 · Updated 5 times

Summary

This early-stage trial tests a new gel called Amicidin-β, applied directly into infected surgical or traumatic wounds during a procedure. The main goal is to see if it is safe and easy for surgeons to use. About 44 adults will take part, comparing standard care alone to standard care plus the gel.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Amicidin-β topical solution
What this could lead to
If safe, this could lead to a new treatment option for wound infections that is applied directly during surgery.
What could go wrong
This is a very early Phase 1 trial with only 44 people, so safety and effectiveness are not yet proven. It may not work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: * Body Mass Index between 18.5 kg/square meter and 39.9kg/square meter * Surgical or traumatic wound determined by the Investigator to be infected within 90 days of surgery or trauma, with longest dimension between 3 and 15 cm. The diagnosis should include one or more of the following signs or symptoms: * Purulent drainage * Erythema * Surrounding induration * Fever or localized heat surrounding the wound * Reported localized pain or localized tenderness on examination * Infected surgical or traumatic wound that is determined by the Investigator to required an interventional procedure, such as incision, drainage, irrigation, and/or debridement. * If female of childbearing potential, must have been practicing an acceptable method of birth control as judged by the Investigator for at least one month prior to enrollment. * Females of childbearing potential must agree that for the entire duration of the study (about 30 days), they will either practice true abstinence consistent with their preferred and usual lifestyle, or use double contraceptive methods. Main Exclusion Criteria: Patients with any of the following will be excluded: * Surgical or traumatic wound associated with surrounding cellulitis extending ≥10 cm from the wound edge * Confirmed necrotizing fasciitis or gangrenous ulcer * Multiple surgical or traumatic wound infections at different sites * Surgical or traumatic wound infection overlying bone fracture, with radiological evidence of non-union * Surgical or traumatic wound infection with open peritoneal cavity * Surgical or traumatic wound infection extending to an organ space * Surgical or traumatic wound infection extending to implanted surgical hardware or protesis. Note: surgical drains and packing are permitted * Surgical or traumatic wound infection involving head and neck * Surgical or traumatic wound infection involving burn injury * Suspected or confirmed osteomyelitis or septic arthritis * Surgical or traumatic wound infection known or suspected to be caused by fungal or mycobacterial organisms * Wound with diagnosis of neuropathic or diabetic foot ulcer or a previous diagnosis of moderate to severe chronic venous insufficiency of a lower extremity in patients with an infected surgical to traumatic wound of the lower extremity * Wound due to malignancy * Antibiotic therapy for an infection other than the surgical or traumatic wound infection * Patient requires supplemental O2 or mechanical ventilation * Pulse Oximetry (SpO2) reading of ≤ 92% on room air (confirmed by two additional readings ≤92% over 15 min). At geographic locations of high altitude, a lower SpO2 limit (e.g., ≤ 91%) may be used at Investigator's discretion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Surgical wound infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Surgical Wound Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • LifeBridge Health

    RECRUITING

    Baltimore, Maryland, 21215, United States

  • Lundquist Institute

    RECRUITING

    Torrance, California, 90502, United States

  • Snake River Research, PLLC

    RECRUITING

    Idaho Falls, Idaho, 83404, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Washington University in St. Louis

    RECRUITING

    St Louis, Missouri, 631110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.